Covalon Technologies Ltd., a leading advanced medical technologies company, has appointed Kim Crooks as its Chief Operating Officer (COO).
In conjunction with her new executive role, Crooks has also been appointed to Covalon’s Board of Directors.
Crooks returned to Covalon in early 2024 as Senior Vice President of Operations, bringing extensive experience from her prior role as Vice President of Operations at the company from 2012 to 2022. Since rejoining, she has played a critical role in managing production, operations, Quality Assurance, Quality Control, Regulatory Affairs, and Human Resources.
As part of her promotion, Crooks will receive 150,000 stock options, vesting equally over three years, with an exercise price set at the market value of Covalon’s common shares on the grant date.
Both her board appointment and stock option grant are pending approval from the TSX Venture Exchange.
